Skip to main content
. Author manuscript; available in PMC: 2018 Aug 14.
Published in final edited form as: Leukemia. 2018 Apr 7;32(8):1818–1822. doi: 10.1038/s41375-018-0032-1

Figure 2. Integration of genomic, phosphoproteomics and mass cytometry data to rationalize kinase inhibitors sensitivity.

Figure 2

(a) Viability of AML cells within the indicated genotype/phenotype groups after treatment with MEKi. (b) Sensitivity of NRAS/BRAF/CDs+ positive cells to MEKi as a function of the indicated factors. (c) FLT3/PKCi sensitivity of AML cells with the indicated phenotype/genotype. Phosphorylations are denoted as (hi) and (lo) based on a greater or lower phosphorylation than the median across all cases. Significance was assessed by Mann-Whitney test.